Private Cloud: The Strategic Engine Behind NSE DC's Tech Evolution
Sampath Manickam, CTO, National Stock Exchange spoke about how private cloud is the the strategic engine behind NSE DC's tech evolution
This talk was a part of ETCIO Annual Conclave 2025, Goa, May 29-June 1
Advertisement
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India.com
5 hours ago
- India.com
THIS company stock surges over 19 percent after..., it outpaced the performance of...
सेफ इंवेस्टमेंट भी जरूरी New Delhi: Shares of Balaxi Pharmaceuticals, a Hyderabad-based pharmaceutical company, witnessed a significant surge on Monday, August 11, 2025. The stock, which belongs to the small-cap category, surged as much as 19 per cent on the National Stock Exchange. This surge was particularly noteworthy as it outpaced the performance of the equity benchmark indices Sensex and Nifty, which also started the trading session in positive territory. The positive start was attributed to fresh foreign fund inflows and a rally in the US markets, making Balaxi's surge a standout event in the market. The stock opened in the green at Rs 49, up from its previous close of Rs 43.67 on the BSE. It further touched the intraday high of Rs 52, a gain of 19.07 per cent from the last close. As of last seen, the stock was trading at Rs 49.74. It's important to note that the stock's 52-week high is Rs 127.45, indicating its potential for growth, while the 52-week low is Rs 42.56, reflecting its stability. The company's market cap is Rs 271.95 crore, further underlining its long-term performance. Technically, the stock is currently trading higher than the 5-day and 20-day moving averages, which are short-term indicators of the stock's recent performance. However, it is trading lower than the 50-day, 100-day, and 200-day moving averages, which are longer-term indicators. This suggests that while the stock has shown recent strength, it is still facing challenges in the medium to long term. Quarterly Results Despite a challenging quarter, the company demonstrated resilience, reporting a net profit of Rs 0.19 crore in the April-June quarter of the financial year 2025-26, a decrease from Rs 1.38 crore in the same quarter a year ago. According to the information shared, the company's revenue from operations stood at Rs 16.71 crore in the quarter under concern. This is down by 12.18 per cent from Rs 19.03 crore in the same quarter in the previous year. Also, EBITDA stands at Rs 1.00 crore in June 2025 down 57.63 per cent from Rs 2.36 crore in June 2024.
&w=3840&q=100)
Business Standard
5 hours ago
- Business Standard
Last day! All Time Plastics IPO closes today; subscription rises 4x, GMP 2%
All Time Plastics IPO Day 3 update: The three-day subscription window to bid for the initial public offering (IPO) of plastic houseware products company All Time Plastics is set to conclude today, August 11, 2025. The ₹400.6 crore issue, which opened for subscription on Thursday, August 7, has received a muted response from investors so far. According to data from the National Stock Exchange (NSE), the All Time Plastics IPO received bids for 42.05 million equity shares against 10.54 million shares on offer as of 2:30 PM on Monday. This reflects an oversubscription of only 4 times. Among the individual categories, non-institutional investors (NIIs) placed the highest number of bids, oversubscribing their reserved category by 5.77 times. This was followed by retail investors, who bid 3.76 times. The qualified institutional buyer's quota was booked 3.15 times per cent. All Time Plastics IPO GMP According to the sources tracking unofficial markets, All Time Plastics shares were trading at around 282, reflecting a grey market premium (GMP) of ₹7 or 2.55 per cent over the upper end of the price band of ₹260 to ₹275. All Time Plastics IPO details The public offering of All Time Plastics comprises a combination of a fresh issue of 10.2 million equity shares worth ₹280 crore and an offer for sale (OFS) of 4.4 million shares worth ₹120.6 crore. Kailesh Punamchand Shah, Bhupesh Punamchand Shah, and Nilesh Punamchand Shah are the promoter selling shareholders. The IPO is priced in the range of ₹260-275 per share, with a lot size of 54 shares. Investors can bid for a minimum of 54 shares and in multiples thereof. A retail investor would need a minimum of ₹14,850 to bid for one lot at the upper end price. The maximum limit for retail investors is 13 lots (702 shares), amounting to an investment of ₹1,93,050. As the subscription window concludes today, the basis of allotment for All Time Plastics IPO shares is likely to be finalised on Tuesday, August 12, 2025. The successful allottees will receive the company's shares in their demat accounts by Wednesday, August 13, 2025. All Time Plastics shares are slated to list on the NSE and BSE, tentatively on Thursday, August 14, 2025. Kfin Technologies is the registrar of the issue. Intensive Fiscal Services and DAM Capital Advisors are the book-running lead managers. According to the red herring prospectus (RHP), the company proposes to utilise the net fresh issue proceeds for prepayment or repayment of debt, purchase of equipment and machinery for the Manekpur facility and general corporate purposes.
&w=3840&q=100)
Business Standard
5 hours ago
- Business Standard
Sai Life Sciences shares surge 11% in 2 days on strong Q1 earnings
Sai Life Sciences share price: Shares of Sai Life Sciences hit a new high of ₹874.80, as they rallied 6 per cent on the National Stock Exchange (NSE) in Monday's intra-day trade. In the past two trading days, the stock price of the pharmaceutical company has surged 11 per cent after it reported strong earnings for the quarter ended June 2025 (Q1FY26). It has bounced back 38 per cent from its 52-week low of ₹635.30 touched on April 9, 2025. At 01:59 PM, Sai Life Sciences was quoting 5 per cent higher at ₹873.60, as compared to a 0.63 per cent rise in Nifty 50. The average trading volumes on the counter jumped over threefold. A combined of around 2.4 million shares changed hands on the NSE and BSE. Sai Life Sciences made its stock market debut on December 18, 2024. Currently, the stock is trading 59 per cent over its issue price of ₹549 per share. Track LIVE Stock Market Updates Here Sai Life Sciences Q1 results In Q1FY26, Sai Life Sciences, an innovator-focused, contract research, development and manufacturing organisation (CRDMO), reported profit after tax at ₹60 crore, driven by healthy revenue from operations. The company had posted a loss of ₹13 crore in the year-ago quarter (Q1FY25). Earnings before interest, tax, depreciation, and amortisation (Ebitda) stood at ₹125 crore, surging 303 7.6 per cent year-on-year (Y-o-Y). Margins improved to 25 per cent from 11 per cent. Margins expansion driven by operating leverage, scale efficiencies, and improved productivity across the company's sites. Revenue from operations grew 77 per cent Y-o-Y at ₹496 crore, against ₹280 crore in Q1FY25. The revenue growth was led by 113 per cent growth in the CDMO segment and a 38 per cent rise in Discovery revenues, enabled by deeper engagement with global clients. During the quarter, the company inaugurated new Biology Labs that significantly strengthen the company's Integrated Discovery platform and enhance the ability to handle greater molecular complexity. Sector outlook The $250 billion global CRDMO market, comprising $90 billion in Contract Research (CROs) and $160 billion in CDMOs, is projected to grow at a 13 per cent compounded annual growth rate (CAGR) through FY27, with CROs growing at 10 per cent and CDMOs at 14 per cent. While global CDMO players shift focus to large molecules, Indian firms are capitalising on the small molecule CRDMO gap, benefiting from cost-efficient manufacturing, increased FDI, and government initiatives like the PLI scheme. Additionally, the US's efforts to diversify from China present opportunities for India's CDMO sector, said Aditya Birla Capital in an IPO note. About Sai Life Sciences The company offers integrated solutions spanning medicinal chemistry, process development, clinical and commercial manufacturing, and advanced technology platforms.
